Literature DB >> 16242626

Progressive supranuclear palsy: a systematic review.

L Rampello1, V Buttà, R Raffaele, I Vecchio, G Battaglia, G Cormaci, A Alvano.   

Abstract

The progressive supranuclear palsy (PSP) is a rapidly progressing degenerative disease belonging to the family of tauophaties, characterized by the involvement of both cortical and subcortical structures. Although the pathogenesis of PSP is still uncertain, genetic, biochemical, and immunohistochemical studies have been performed and are reviewed here. Genetic factors, oxidative damage, neurotoxins, and environmental factors contribute to tau deposition in the cerebral areas involved in PSP. Symptoms originate from the ensuing dysfunction of dopaminergic, GABAergic, cholinergic, and noradrenergic pathways. Recent advances in neuroradiological and instrumental examinations facilitate the diagnosis and have gained new insights into the pathophysiology of PSP, although the primary cause of the disease is unknown and disease-modifying drugs are not yet available.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242626     DOI: 10.1016/j.nbd.2005.03.013

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  13 in total

Review 1.  Frontotemporal dementia.

Authors:  Erik D Roberson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

2.  Longitudinal follow-up of late-onset Alzheimer disease families.

Authors:  R M Carney; M A Slifer; P I Lin; P C Gaskell; W K Scott; C F Potocky; C M Hulette; K A Welsh-Bohmer; D E Schmechel; J M Vance; M A Pericak-Vance
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-07-05       Impact factor: 3.568

3.  Long-term exercise training for an individual with mixed corticobasal degeneration and progressive supranuclear palsy features: 10-year case report follow-up.

Authors:  Teresa M Steffen; Bradley F Boeve; Cheryl M Petersen; Leah Dvorak; Kejal Kantarci
Journal:  Phys Ther       Date:  2013-10-10

4.  Sound naming in neurodegenerative disease.

Authors:  Maggie L Chow; Simona M Brambati; Maria Luisa Gorno-Tempini; Bruce L Miller; Julene K Johnson
Journal:  Brain Cogn       Date:  2010-01-20       Impact factor: 2.310

5.  Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathology.

Authors:  Leo F McCluskey; Lauren B Elman; Maria Martinez-Lage; Vivianna Van Deerlin; Wuxing Yuan; Dana Clay; Andrew Siderowf; John Q Trojanowski
Journal:  Arch Neurol       Date:  2009-01

6.  Glycolitic enzymes are targets of oxidation in aged human frontal cortex and oxidative damage of these proteins is increased in progressive supranuclear palsy.

Authors:  A Martínez; E Dalfó; G Muntané; I Ferrer
Journal:  J Neural Transm (Vienna)       Date:  2007-08-21       Impact factor: 3.575

7.  [Atypical Parkinson syndromes].

Authors:  A Strzelczyk; J C Möller; M Stamelou; A Matusch; W H Oertel
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

8.  Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.

Authors:  Hye-Jin Park; Kang-Woo Lee; Stephanie Oh; Run Yan; Jie Zhang; Thomas G Beach; Charles H Adler; Michael Voronkov; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
Journal:  J Neuropathol Exp Neurol       Date:  2018-02-01       Impact factor: 3.685

9.  Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report.

Authors:  Patrizio Sale; Fabrizio Stocchi; Daniele Galafate; Maria Francesca De Pandis; Domenica Le Pera; Ivan Sova; Manuela Galli; Calogero Foti; Marco Franceschini
Journal:  Front Hum Neurosci       Date:  2014-04-17       Impact factor: 3.169

10.  Assessment of brain reference genes for RT-qPCR studies in neurodegenerative diseases.

Authors:  Rasmus Rydbirk; Jonas Folke; Kristian Winge; Susana Aznar; Bente Pakkenberg; Tomasz Brudek
Journal:  Sci Rep       Date:  2016-11-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.